<DOC>
	<DOC>NCT00057473</DOC>
	<brief_summary>This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.</brief_summary>
	<brief_title>A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>children 121 years of age confirmed diagnosis of measurable solid tumor, including brain tumor, which has progressed on or after standard therapy, or for which no effective standard therapy is known at least 4 weeks since last dose of immunotherapy, radiotherapy, or chemotherapy no more than 3 prior chemotherapies no symptomatic brain metastases</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>unspecified childhood solid tumor, protocol specific</keyword>
</DOC>